RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Initially, it was thought that fusion proteins act as negative regulators for wild-type RUNX1 in a dominant-negative fashion, which enables CML’s progression to blast crisis phase by the generation of drug resistance [3–6].